Mikhail Blagosklonny is a renowned author of more than 260 articles published in various peer-reviewed journals. These papers have received more than 25,000 citations, which has made him attain an h-index of 83. Dr. Blagosklonny is the current associate editor of Cancer Biology Therapy and Cell Death Differentiation. He has also served on the editorial board of Autophagy, Cancer Research, PLOS ONE, Intenational J Cancer and the founding and current Cell Cycle editor-in-chief. His areas of interest in research range from cellular and molecular biology to medical investigations that include cell cycle, signal transduction, anticancer therapeutics, cellular senescence and fresh anticancer strategies. He increased his studies on signal transduction from cancer to the area of aging On tandfonline.com. This revealed potential targets useful for slowing down age-related diseases and aging.
Education and Career
He started off his career as an associate professor of medicine after getting appointed at the New York Medical College, Valhalla in 2002. He then became a senior scientist at impactjournals.com at the Ordway Research Institute in Albany, New York. He held onto this position until 2009 when Blagosklonny was appointed as the Professor of Oncology, Roswell Park Cancer Institute.
Aging and the use of Rapamycin
Blagosklonny has come up with a hypothesis looking at the probable role of TOR signaling in cancer and aging. He proposes the use of rapamycin, which is a popular drug used for cancer as a potential treatment for extension of life. Rapamycin when administered in rational schedules and doses can prevent nephropathy, retinopathy and beta-cell failure without any side effects. Dr. Blagosklonny is known and considered as one of rapamycin’s passionate advocates in the longevity research.
Role at Roswell Park Cancer Institute
According to the Senior Vice-President at Roswell Park’s Basic Science and Chairman of Department of the Cell Stress Biology at https://www.linkedin.com/in/mikhail-blagosklonny-91abb531, Andrei V. Gudkov, Mikhail is a pre-eminent researcher. Andrei praised his unique concepts that he has developed in cancer therapy and biology at the time when Dr. Blagosklonny was recruited at Roswell Park (April 15, 2009). Dr. Blagosklonny has helped in facilitating the development of fresh anti-cancer methods and strategies and various cancer prevention and therapy methods. He has been able to achieve all the above due to his approaches and ideas that include protecting normal body cells from chemo- and radiotherapy, tissue-specific and anti-tissue therapy, anticancer drugs selective combination and the slowdown of cancer via slowing down the aging process in organisms.